Build your first fully functional, Java-based AI agent using familiar Spring conventions and built-in tools from Spring AI.

PLEASANTON, Calif., March 10, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the acquisition of Ostro, the leading brand engagement platform for life sciences that gives patients and ...

For the quarter ended January 2026, Veeva Systems (VEEV) reported revenue of $835.95 million, up 16% over the same period last year. EPS came in at $2.06, compared to $1.74 in the year-ago quarter.

Veeva's laser focus on the life sciences industry has made it a leader in this corner of the cloud market. The company could grow its revenue -- and share price -- at a good clip in the next four ...

The past six months have been rough for Veeva Systems (NYSE: VEEV). The stock has declined 35% over this period as the market fears that mounting competition will lead to disappointing financial ...

As noted previously, when Veeva ended its licence agreement with Salesforce, it not only triggered a battle royale for domination of big pharma CRM, it began the first massive use case for adoption of ...

The latest announcement is out from Veeva Systems ( (VEEV)). On January 5, 2026, Veeva Systems announced that its board had authorized the company’s first-ever share repurchase program, allowing the ...

Veeva Systems (NYSE: VEEV) is currently in Phase 18, the final stage of its 18-phase Adhishthana cycle on the weekly charts. The company recently reported earnings, and the stock has fallen sharply ...

Veeva Systems Inc. (NYSE:VEEV) is one of the best digital health stocks to buy now. On November 4, 2025, Veeva announced that its Veeva Basics solution has been adopted by “more than 100 biotechs” to ...

Veeva Systems Inc. (NYSE:VEEV) reported better-than-expected earnings for the second quarter on Wednesday. The company posted quarterly earnings of $1.99 per share which beat the analyst consensus ...

The yearslong legal kerfuffle between IQVIA and Veeva Systems has come to a close, with the former adversaries setting aside their differences to launch a series of clinical and commercial ...